NARSAD-Funded Imaging Study Shows Positive Improvement in Treatment of Cognitive Impairment in Schizophrenia

(Great Neck, N.Y. – April, 02, 2010) — Top line results of an imaging study funded by NARSAD (National Alliance for Research on Schizophrenia and Depression) and Allon Therapeutics showed that 12-week treatment with davunetide, a neuroprotective drug candidate developed by Allon, resulted in a statistically significant increase in levels of a biomarker that is an important indicator of brain cell health………

This study was adapted from Allon Therapeutics Inc.

Reported by NARSAD

Submitted by Anna

Speak Your Mind